This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Comments
Loading...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • B. Riley Securities analyst Kalpit Patel initiated coverage on ArriVent BioPharma, Inc. AVBP with a Buy rating and announced a price target of $37. ArriVent BioPharma shares closed at $19.60 on Wednesday. See how other analysts view this stock.
  • Goldman Sachs analyst Noah Poponak initiated coverage on Amentum Holdings, Inc. AMTM with a Neutral rating and announced a price target of $21. Amentum Holdings shares closed at $19.03 on Wednesday. See how other analysts view this stock.
  • Morgan Stanley analyst Judah Frommer initiated coverage on Celldex Therapeutics, Inc. CLDX with an Overweight rating and announced a price target of $46. Celldex Therapeutics shares closed at $19.95 on Wednesday. See how other analysts view this stock.
  • JP Morgan analyst Detlef Winckelmann initiated coverage on International Paper Company IP with an Overweight rating and announced a price target of $59. International Paper shares closed at $52.62 on Wednesday. See how other analysts view this stock.
  • Scotiabank analyst Patrick Colville initiated coverage on Microsoft Corporation MSFT with a Sector Outperform rating and announced a price target of $470. Microsoft shares closed at $387.82 on Wednesday.  See how other analysts view this stock.

Considering buying MSFT stock? Here’s what analysts think:

Read This Next:

Photo: Shutterstock

AMTM Logo
AMTMAmentum Holdings Inc
$18.70-0.32%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
-
Growth
-
Quality
-
Value
29.76
Price Trend
Short
Medium
Long
Got Questions? Ask
Which biotech stocks may surge with ArriVent?
How will Amentum Holdings impact defense sector?
What could drive Celldex Therapeutics share prices higher?
Which paper companies might benefit from International Paper?
How could Microsoft's growth influence tech ETFs?
What investments align with bullish sentiment on MSFT?
Which analyst ratings could indicate market trends?
How does sector performance reflect on analyst targets?
Which emerging tech companies could rival Microsoft?
What risks could challenge ArriVent BioPharma stock performance?
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In: